Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Robert M, Fielding"'
Publikováno v:
Clinical Pharmacology in Drug Development. 3:4-12
This Phase 1, single-center, double-blind, placebo-controlled, three-period study assessed cardiovascular safety of CX157, a specific Reversible Inhibitor of Monoamine Oxidase A (RIMA), following the oral administration of tyramine. In Period 1, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bd8b8e415838d040dd947bedb2e08ef
https://doi.org/10.1002/cpdd.61
https://doi.org/10.1002/cpdd.61
Autor:
Steve Rosenfeld, Xiaolin Wang, Betty Lawrence, Mona Shing, Robert M. Fielding, Jean Paul Castaigne, Patrick Y. Wen, Christina A. Meyers, April F. Eichler, Eric T. Wong, Andrew Brenner, David Schiff, John Sarantopoulos, Jan Drappatz, Tom Mikkelsen, Morris D. Groves, Stephen M. Kelsey, Kelly Elian
Publikováno v:
Clinical Cancer Research. 19:1567-1576
Purpose: GRN1005 is a peptide–drug conjugate with the ability to penetrate the blood–brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor–related protein-1. We conducted a first-in-human phase I trial of GRN1005
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc636801518078d5ba9fad5ae7a72e3d
https://doi.org/10.1158/1078-0432.ccr-12-2481
https://doi.org/10.1158/1078-0432.ccr-12-2481
Publikováno v:
Journal of Dietary Supplements. 5:373-382
Many different products containing Noni (Morinda citrifolia) fruit extracts are sold throughout the world for health restoration and maintenance. Despite a large business enterprise fueling Noni's popularity, there is a lack of standardization of pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e05c8247ea86da202aae7ab97097fa
https://doi.org/10.1080/19390210802519671
https://doi.org/10.1080/19390210802519671
Autor:
S. Dean Allison, Lefteris C. Zacharia, Robert M. Fielding, Edwin K. Jackson, Kathleen M. Holland, Raghvendra K. Dubey, Claude A. Piché
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 309:1093-1097
Previous in vivo studies indicate that 2-hydroxyestradiol (2OHE) attenuates cardiovascular and renal diseases. In vitro studies suggest that the biological effects of 2OHE are mediated by 2-methoxyestradiol (2MEOE) after methylation of 2OHE by catech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d5594fd54c986a2c210849c98a781c
https://doi.org/10.1124/jpet.103.062505
https://doi.org/10.1124/jpet.103.062505
Autor:
Jean W. Lee, Donald N. Buell, Robert M. Fielding, Ihor Bekersky, Thomas J. Walsh, Dawna Dressler
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:834-840
Unilamellar liposomal amphotericin B (AmBisome) (liposomal AMB) reduces the toxicity of this antifungal drug. The unique composition of liposomal AMB stabilizes the liposomes, producing higher sustained drug levels in plasma and reducing renal and he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d777d5a26eabcd3d6d4055a580edede5
https://doi.org/10.1128/aac.46.3.834-840.2002
https://doi.org/10.1128/aac.46.3.834-840.2002
Autor:
Ihor Bekersky, Robert M. Fielding, Dawna E. Dressler, Sandra Kline, Donald N. Buell, Thomas J. Walsh
Publikováno v:
The Journal of Clinical Pharmacology. 41:963-971
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b756dde9121ceada811b25ef1cd2dcce
https://doi.org/10.1177/009127000104100906
https://doi.org/10.1177/009127000104100906
Autor:
Ihor Bekersky, Robert M. Fielding, Donald N. Buell, Dawna E. Dressler, Thomas J. Walsh, Sandra Kline
Publikováno v:
Journal of Clinical Pharmacology. 41:963-971
Amphotericin B (AmB) in small unilamellar liposomes (AmBisome) provides higher plasma concentrations and greater safety than the conventional deoxycholate formulation. The authors compared the disposition of the liposome's drug and cholesterol compon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d65909bb8c203f821068e9ac72d9e64d
https://doi.org/10.1177/00912700122010942
https://doi.org/10.1177/00912700122010942
Autor:
Robert M. Fielding
Publikováno v:
Pharmaceutical Research. 18:238-242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ddd6bfd4e6a314ecba5efc7c9f9bfab
https://doi.org/10.1023/a:1011096821662
https://doi.org/10.1023/a:1011096821662
Autor:
Thomas J. Walsh, Robert M. Fielding, Richard Hiles, Ihor Bekersky, Garry Boswell, Donald N. Buell
Publikováno v:
Pharmaceutical Research. 17:1494-1502
Purpose. Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue exposures, the potential for drug accumulation or delayed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff61dacd8f45051e60384ebc2c60571d
https://doi.org/10.1023/a:1007605024942
https://doi.org/10.1023/a:1007605024942
Publikováno v:
Pharmaceutical Science & Technology Today. 2:230-236
Amphotericin B has been the mainstay of systemic antifungal therapy for over 30 years, despite its serious side-effects, and, although numerous alternative antifungal agents have been developed, none to date has matched the efficacy of amphotericin B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b634d283e9fdbb34b407ae8370e39dc
https://doi.org/10.1016/s1461-5347(99)00160-1
https://doi.org/10.1016/s1461-5347(99)00160-1